Head-to-head evidence
Ciltacabtagene autoleucel vs Idecabtagene vicleucel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Ciltacabtagene autoleucel
Marketed by Johnson & Johnson and partners
NCT03548207 · Phase 1/2 · completed
This was an open-label, single-group study with no randomized comparator and no blinding. Although the overall response rate among treated participants was high (e.g., 97.1% in the Phase 2 US population with 95% CI 89.8-99.6), the lack of a control arm means the results cannot be attributed to the drug with confidence. Uncontrolled single-arm evidence is inherently limited regardless of the response rate observed.
Next expected readout: February 2027 · NCT04133636 (registry estimate)
Idecabtagene vicleucel
Marketed by Bristol-Myers Squibb
NCT03651128 · Phase 3 · completed
Randomized, open-label Phase 3 trial (n=386) demonstrating significant improvement in PFS vs standard regimens in relapsed/refractory multiple myeloma (NEJM 2023).
Next expected readout: May 2027 · NCT05393804 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ciltacabtagene autoleucel's landscape · Idecabtagene vicleucel's landscape